Are neck and décolletage fillers FDA approved in 2026?

Yes—but only for exact products and labeled uses. FDA approved SKINVIVE by JUVÉDERM for specified neck-line injection in adults over 21 on June 11, 2026. For RADIESSE, FDA records a March 31, 2026 decision and an April 7, 2026 approval-order date for 1:2 sterile-saline dilution and subdermal décolleté-wrinkle correction in patients 22 and older. Neither decision covers all fillers or neck and chest uses.¹²³⁵

This is a useful regulatory change precisely because it is narrow. A consultation should match product, preparation, anatomy, plane, age, device labeling, training, and intended endpoint word for word.

Keep the two 2026 approvals separate

The SKINVIVE supplement expanded an earlier cheek-smoothness indication. Its neck labeling identifies the product, neck-line endpoint, intradermal and/or subdermal route, age boundary, and permitted needle or needle-plus-cannula use.¹² “Skin booster approved for the neck” loses several of those constraints.

FDA’s PMA database lists March 31, 2026 as the decision date for P050052/S162; the associated approval order is dated April 7, 2026.³⁵ The order identifies a particular 1:2 dilution with sterile saline, subdermal placement, décolleté-wrinkle endpoint, and age boundary.³ It also conditions distribution on a device-specific training program and includes a post-approval study of whether décolleté treatment interferes with breast radiographic imaging. Those details belong in the current conversation, not only in a launch headline.

Identify the anatomy being sold

“Neck,” “chest,” and “décolletage” can be used loosely. Draw the treatment field. Horizontal neck lines, thin crepey surface texture, vertical platysma bands, submental fat, skin laxity, necklace lines extending laterally, and wrinkles over the upper chest are different targets.

Ask the provider to state which finding the labeled indication addresses and which parts of the proposed plan are outside it. FDA approval of one filler indication does not establish that filler is the correct mechanism for another concern or that every use in the broad region is on label.⁴ The SKINVIVE and skin-booster guide explains why product category, intended endpoint, and injection plan must remain separate.

Read the study endpoint, not just the approval verb

The SKINVIVE pivotal study used a validated transverse-neck-line scale, a no-treatment control period, and a primary response defined by at least a one-grade improvement at the specified time point.² That is evidence for the approved endpoint and population. It does not prove permanent change, correction of severe loose skin, superiority to every alternative, or the same outcome with another product or technique.

For RADIESSE, the approval order’s post-approval requirements are part of the current record.³ A required ongoing imaging study should not be misstated as proof that breast imaging can never be affected. Preserve the treatment history and tell the imaging facility about material placed near the breast field; the breast-imaging after cosmetic surgery guide provides a broader record checklist.

Preserve product and injection traceability

Before treatment, record:

• sealed box and syringe, exact product name, lot, expiration, and patient label;
• PMA supplement and current instructions for use;
• for RADIESSE, original product volume, sterile-saline source, exact 1:2 preparation record, preparer, time, and final volume;
• treatment map, depth or plane, volume by region, and needle or cannula;
• clinician identity, Florida license, and product-specific training where required;
• consent, photographs, follow-up dates, and complication contact; and
• any earlier filler, surgery, energy treatment, breast imaging, or permanent material in the region.

FDA’s filler guidance describes common injection-site effects and rare but serious complications from unintended blood-vessel injection, including tissue death, vision problems, stroke, and death.⁴ Those category risks remain relevant even when the product and indication are approved. Approval is not a no-risk designation.

Compare a consultation in six questions

1. What is the exact concern? Name and map transverse line, chest wrinkle, laxity, band, fat, texture, scar, or another target.
2. Which exact product? Match sealed syringe, lot, current labeling, PMA supplement, and stated indication.
3. Is the preparation exact? Record dilution, diluent, volumes, mixing, timing, and final concentration when the approved use depends on them.
4. Does the plan match the label? Compare age, anatomy, depth, endpoint, injection tool, warnings, contraindications, and training.
5. What evidence supports any extension? Have the provider label off-label elements and identify evidence without borrowing the approved indication.
6. Who owns follow-up? Preserve product and treatment records, planned checks, urgent contact, imaging disclosure, and complication response.

The decisive question is: “Can the clinic match this sealed product, preparation, anatomy, injection plane, age, endpoint, and trained provider to the current FDA record?”